Your browser doesn't support javascript.
loading
The role and application of vesicles in triple-negative breast cancer: Opportunities and challenges.
Wei, Ya-Nan; Yan, Chun-Yan; Zhao, Meng-Lu; Zhao, Xi-He.
Affiliation
  • Wei YN; Department of Clinical Oncology, Sheng jing Hospital of China Medical University, Shenyang 110022, People's Republic of China.
  • Yan CY; Department of Clinical Oncology, Sheng jing Hospital of China Medical University, Shenyang 110022, People's Republic of China.
  • Zhao ML; Department of Clinical Oncology, Sheng jing Hospital of China Medical University, Shenyang 110022, People's Republic of China.
  • Zhao XH; Department of Clinical Oncology, Sheng jing Hospital of China Medical University, Shenyang 110022, People's Republic of China.
Mol Ther Oncolytics ; 31: 100752, 2023 Dec 19.
Article in En | MEDLINE | ID: mdl-38130701
ABSTRACT
Extracellular vesicles (EVs) carry DNA, RNA, protein, and other substances involved in intercellular crosstalk and can be used for the targeted delivery of drugs. Triple-negative breast cancer (TNBC) is rich in recurrent and metastatic disease and lacks therapeutic targets. Studies have proved the role of EVs in the different stages of the genesis and development of TNBC. Cancer cells actively secrete various biomolecules, which play a significant part establishing the tumor microenvironment via EVs. In this article, we describe the roles of EVs in the tumor immune microenvironment, metabolic microenvironment, and vascular remodeling, and summarize the application of EVs for objective delivery of chemotherapeutic drugs, immune antigens, and cancer vaccine adjuvants. EVs-based therapy may represent the next-generation tool for targeted drug delivery for the cure of a variety of diseases lacking effective drug treatment.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Mol Ther Oncolytics Year: 2023 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Mol Ther Oncolytics Year: 2023 Document type: Article Country of publication: